DKTK-Studienregister

DetailsucheDetailsuche
Klicken Sie auf Detailsuche, um z.B. nach Therapielinie, molekularem Marker oder Rekrutierungsstatus zu suchen.
FreitextsucheFreitextsuche
Sie können hier nach dem Studienkurzcode oder einem Teil des Studientitels suchen.
Studienauswahl
Zentren
Status der Studie

» Hämatologische Neoplasien » NHL: diffuses, großzelliges B-Zell-Lymphom

Alle Linien

X4P-001-204
A phase 1b trial of Mavorixafor, an oral CXCR4 antagonist, in combination with Ibrutinib in patients with Waldenstrom’s Macroglobulinemia (WM) whose tumors express mutations in MYD88 and CXCR4 A study of Mavorixafor in combination with Ibrutinib in participants with Waldenstrom's Macroglobulinemia (WM) whose Tumors Express Mutations in MYD88 and CXCR4 (Aktiv)

Erstlinie

GLA 2018-03 - COPA-R-CHOP
Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL (Aktiv)

MOR208C310 - frontMIND
Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zur Wirksamkeit und Sicherheit von Tafasitamab plus Lenalidomid zusätzlich zu R-CHOP versus R-CHOP bei zuvor unbehandelten, hochintermediären und hochriskanten Patienten mit diffusem großzelligem B-Zell-Lymphom (DLBCL) (Aktiv)

NP40126
A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas (Aktiv)

Zweitlinie oder später

AMG 562 20170533
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma (Aktiv)

Amgen 20180257
A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients (Aktiv)

BGB-3111-212
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma (Aktiv)

CC-220-NHL-001
A Phase 1/2, Multicenter, Open-Label Study to Assess Safety, Pharmacokinetics, and preliminary efficacy of CC-220, alone and in combination with an anti-CD20 Monoclonal Antibody (MAB) in subjects with relapsed or refractory Lymphomas (Aktiv)

CITADEL-202
The purpose of this study is to assess the safety and efficacy of INCB050465 in subjects with relapsed or refractory diffuse large B-cell lymphoma. (Aktiv)

CITADEL-204
The purpose of this study is to evaluate the safety and efficacy of two INCB050465 treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor. (Aktiv)

DALY 2-EU
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (Aktiv)

JCAR017-FOL-001 - TRANSCEND FL
A study to evaluate the efficacy and safety of JCAR017 in adult subjects with a type of cancer that affects B-cells, a type of white blood cell. (Aktiv)

LYMRIT-37-05
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) (Aktiv)

MAK683
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies (Aktiv)

NIVEAU
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of B-cell lymphoma (Aktiv)

DKTK-Studienregister
Dr. N. Gökbuget, Dipl.-Biol. K. Ihrig | Ohne Gewähr für Richtigkeit oder Vollständigkeit | ccp@dkfz.de